Abstract. Growth hormone (GH) plays a pivotal role in the regulation of growth, development and body composition. In order to provide new insights into estrogenic endocrine disruptor (ED) activities in the pituitary gland and the potential role played by estrogen receptors (ERs) in mediating their effects in vivo, we examined GH expression in the pituitary gland of an immature rat model. At postnatal day 14, immature rats were treated with various doses of 4-tertoctylphenol (OP), p-nonylphenol (NP) and bisphenol A (BPA), and the GH mRNA and protein expression levels were analyzed by real-time quantitative PCR and western blot/immunohistochemistry (IHC), respectively. An anti-estrogen (ICI 182780) was used to examine the potential involvement of ERs in ED-induced GH expression during critical windows of development. GH mRNA expression increased significantly 48 h after treatment with a high dose (600 mg/ kg body weight [BW]) of OP or NP. However, this induction was abolished completely by co-treatment with ICI 182780. No significant difference in GH mRNA expression was observed following treatment with BPA or co-treatment of BPA with the anti-estrogen. Exposure to high doses (600 mg/kg BW) of these EDs significantly enhanced GH protein expression in the rat pituitary gland, whereas pretreatment with ICI 182780 markedly reduced this expression. Taken together, we have demonstrated for the first time that in vivo exposure to EDs can induce GH mRNA and protein expression in the rat pituitary gland and that their activities may involve an ER-mediated signaling pathway. These results may provide critical evidence for ED-induced dysregulation of pituitary GH expression and thus may be important for elucidating the potential impacts of EDs in altered body growth and development and for predicting the health risks of ED exposure in humans and wildlife. Key words: Endocrine disruptor, Estrogenicity, Growth hormone, Pituitary gland, Rat (J. Reprod. Dev. 55: [206][207][208][209][210][211][212][213] 2009) rowth hormone (GH) plays a pivotal role in growth and development during puberty and is a member of a family of evolutionarily-related hormones that include prolactin (PRL) and placental lactogen [1] . In addition, GH performs important functions in metabolism and body composition [2] . GH activity can be regulated directly via sex steroids, which control GH release, or indirectly by modulation of insulin-like growth factor (IGF)-I [3] . Although most of its growth-promoting activity is mediated by IGF-I activation [1] , studies have indicated that changes in circulating levels of sex steroids may lead to modulation of GH synthesis and release of GH from the anterior lobe of the pituitary [4] . In humans, GH regulates growth in childhood [5] , and most endocrine disorders that influence body growth and development affect GH levels during this critical window. Recent reports have indicated a positive correlation between GH and estrogen levels in prepubertal girls and boys [6, 7] . The effects of estrogen stimulation on growth depend strongly upon pituitary GH [5] , and estrogen regulates GH release in adults; higher levels are observed in women than in men [6] .
rowth hormone (GH) plays a pivotal role in growth and development during puberty and is a member of a family of evolutionarily-related hormones that include prolactin (PRL) and placental lactogen [1] . In addition, GH performs important functions in metabolism and body composition [2] . GH activity can be regulated directly via sex steroids, which control GH release, or indirectly by modulation of insulin-like growth factor (IGF)-I [3] . Although most of its growth-promoting activity is mediated by IGF-I activation [1] , studies have indicated that changes in circulating levels of sex steroids may lead to modulation of GH synthesis and release of GH from the anterior lobe of the pituitary [4] . In humans, GH regulates growth in childhood [5] , and most endocrine disorders that influence body growth and development affect GH levels during this critical window. Recent reports have indicated a positive correlation between GH and estrogen levels in prepubertal girls and boys [6, 7] . The effects of estrogen stimulation on growth depend strongly upon pituitary GH [5] , and estrogen regulates GH release in adults; higher levels are observed in women than in men [6] .
Although the mechanisms underlying placental GH release remain unclear, this hormone is known to play a major role in the regulation of maternal serum IGF-I levels during pregnancy, and with the exception of lactogenic activity, it exhibits very similar biological effects to pituitary GH [8] . Prolactin (PRL) is a growth promoting protein secreted from the pituitary gland that plays important roles in a variety of processes including growth, metabolism, reproduction, parental behavior and immune responses [9] . Cellular proliferation is considered to be a major function of PRL during body growth and development in mammals [10] . In addition, it appears that PRL performs a wider range of activities than the other pituitary hormones, functioning as both a growth regulator and neurotransmitter [9] . PRL gene expression and secretion appear to be regulated by estradiol (E2). Finally, although PRL and GH share structural similarities [11] , their biological functions remain distinct in different organs [10] .
In the present study, we examined the effect(s) of xenoestrogens on expression and release of GH in the rat pituitary gland. In humans, the physiological effects of estrogens on the pituitary gland have been well documented [12] , and E2 has been shown to exert its biological effects via the hypothalamic-pituitary axis, modulating expression and release of anterior pituitary hormones such as GH and PRL [13, 14] . In rat anterior pituitary cells, E2 stimulates synthesis and release of GH [15] , and the estrogen receptor (ER) signaling pathway mediates E2-induced cellular responses such as proliferation and regulation of hormone synthesis [16] . Recently, E2 has been shown to affect GH activity via both genomic and non-genomic pathways [6] . The non-genomic response may occur rapidly, i.e., within minutes of exposure, whereas the genomic response is delayed and requires at least several hours to become established [17, 18] . Thus, genomic effects may play a significant role in delayed responses to E2 and xenoestrogen exposure. Classically, E2 and estrogenic endocrine disruptors (EDs) exert their biological effects by binding to intracellular ERs, which function as transcription factors.
In vivo, estrogen controls many physiological processes and is involved in the development of reproductive organs, bone, liver and cardiovascular systems [19] . However, a variety of environmental contaminants possess hormonal properties, and EDs that cause a physiological estrogenic response (xenoestrogens) may bind ERs and induce or modulate ER-mediated responses [20, 21] . Phenol-containing molecules, such as 4-tert-octylphenol (OP), pnonylphenol (NP) and bisphenol A (BPA), have been reported to exert weak estrogenic activities in vitro and in vivo [22, 23] . Exposure to OP, NP or BPA results in induction of CaBP-9k expression, a useful biomarker for screening estrogenic EDs, and these activities may involve ERs and ER-mediated pathways in vivo and in vitro [24, 25] . In vitro, these chemicals have been observed to act via an ER-mediated signaling pathway, inducing upregulation of GH and PRL transcription in GH3 cells (unpublished results).
In order to provide new insights into the potential role played by ERs in the activities of xenoestrogens, we examined the induction of GH expression in the pituitary gland of immature female rats in the presence and absence of an ER antagonist (ICI 182780). We used real-time quantitative PCR and Western blot assay/ immunohistochemistry to determine the GH mRNA and protein expression levels, respectively. As a positive control, we measured transcriptional induction of PRL, a well-known biomarker for estrogenic activity.
Materials and Methods

Chemicals
The 17α-ethinylestradiol (EE), OP, NP, BPA and corn oil used in the present study were purchased from Sigma-Aldrich (St. Louis, MO, USA). The ER antagonist ICI 182780 (7α,17β-[9[(4,4,5,5,5-pentafluoropentyl)sulfinyl] nonyl]estra-1,3,5(10)-triene-3,17-diol) was obtained from Tocris (Ellisville, MO, USA).
Animals and treatments
Immature female Sprague-Dawley rats (14-day-old) were obtained from Biolink (Cheongju, Korea). All animals were maintained in polycarbonate cages and used after acclimation to an environmentally-controlled room (temperature 23 ± 2 C, relative humidity 50 ± 10%, frequent ventilation and a 12 h light-dark cycle). The animals were given soy-free pellet food (Samyang, Korea) and provided with tap water ad libitum throughout the experimental period, as described previously [24, 26, 27] . All experimental procedures and animal use were approved by the Ethics Committee of Chungbuk National University.
In the first experiment, immature female rats (n=6 per group) were treated for 3 days with daily subcutaneous (sc) injections of OP, NP or BPA [10, 100 or 600 mg/kg body weight (BW); 3 administrations in total] dissolved in corn oil. The rats were euthanized 48 h after the last treatment. As a positive control, rats were treated with 17α-ethinylestradiol (EE; 50 μg/kg BW), and high doses (up to 600 mg/kg BW) of the chemicals were employed because the binding affinity of these chemicals to steroid receptors appear to be 1,000 to 10,000 times less than described previously [27] . As a negative control, six immature rats received sc injections of corn oil.
In the second experiment, groups (n=6 per group) of immature female rats were either treated with or without an sc injection of ICI 182780 (25 μg per rat) 30 min prior to treatment with high doses (600 mg/kg BW) of OP, NP, BPA or the positive or negative controls (EE or corn oil), as described above. The rats were euthanized 48 h after the last injection. In both experiments, the rat pituitary glands were isolated following euthanization for further RNA and protein extractions as previously described [28] .
Real-time quantitative PCR
Following isolation of the rat pituitary glands, total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions, and the concentration of total RNA was determined by absorbance at 260/280 nm. The gene encoding hypoxanthine-guanine phosphoribosyl transferase (HPRT) was used for normalization of mRNA concentrations between the PCR reactions. Briefly, 2 μg total RNA was reverse transcribed into first-strand cDNA using M-MLV reverse transcriptase (Ambion, Austin, TX, USA) and a 9-mer random primer. A 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) was used for amplification, and reactions were performed with TaqMan Probes specific for rat GH, PRL and HPRT. TaqMan 2X Universal PCR Master Mix was used under the following conditions: 2 min at 50 C, 10 min at 95 C, and then followed 40 cycles of 15 s at 95 C and 1 min at 60 C. All PCR products were analyzed using version 1.3 of the 7300 SDS software (Applied Biosystems).
Western blot assay
Protein was extracted using Proprep solution (Intron, Seoul, Republic of Korea) according to the manufacturer's instructions.
Forty μg of cytosolic protein were separated on 10% SDS-PAGE gels and transferred to PVDF membranes (Amersham Pharmacia Biotech, Rockville, MD, USA) using a tank transfer system (BioRad, Hercules, CA, USA) according to the manufacturer's instructions. Membranes were blocked overnight in PBS Tween containing 5% skim milk prior to incubation with goat polyclonal antibodies specific for pituitary GH or PRL (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and then horseradish peroxidase-conjugated anti-goat antibody (1:2,000; Santa Cruz Biotechnology). Hybridization was visualized using a light chemiluminescent system (Amersham Pharmacia Biotech, Rockville, MD, USA). The GH and PRL levels were quantified with a ChemiDoc XRS System using the Quantity One software (BioRad, Hercules, CA, USA) and normalized against the beta-actin levels of each sample.
Immunohistochemistry (IHC)
IHC was used to detect GH protein signals in the pituitary gland.
Rat pituitary glands were embedded in paraffin, and then sections (5 μm) were deparaffinized in xylene and hydrated in descending grades of ethanol. Endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide in PBS-T for 20 min. Sections were blocked in 10% normal goat serum (NGS) for 2 h at room temperature (RT) and then incubated for 1 h at RT with a goat polyclonal antibody against GH (1:500) dissolved in 10% NGS. After washing with PBS-T, the sections were incubated with a biotinylated anti-goat antibody (1:2,000; Santa Cruz Biotechnology) for 30 min at 37 C and then an avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA) for 30 min at 37 C. Diaminobenzidine (Fast DAB tablets, Sigma) was used as chromogen, and sections were counterstained with hematoxylin and mounted with Permount (Fisher Scientific, Fair Lawn, NJ, USA).
Data analysis
The data were analyzed by one-way ANOVA followed by Tukey's multiple comparison test and are presented as means SD. Data were represented as means ± SD and analyzed by one-way ANOVA followed by Tukey's multiple comparison test. P<0.05 was considered statistically significant.
Results
Dose-dependent effects of EDs on GH mRNA expression
Real-time quantitative PCR was used to examine the dosedependent effects of OP, NP and BPA on induction of GH mRNA (Fig. 1A ). Significant increases in GH mRNA expression were observed 48 h after exposure to high doses (600 mg/kg BW) of OP or NP, whereas no differences were detected at low or medium doses (10 and 100 mg/kg BW). However, no increase in GH transcription was observed following treatment with BPA (10, 100 or 600 mg/kg BW). As expected, a significant increase in GH mRNA expression was observed 48 h after a single injection of EE (50 μg/ kg BW). PRL mRNA expression was used as an indicator of estrogenic ED activity (Fig. 1B) . At 48 h after the final injection, EE and high doses of both OP and NP, were found to enhance PRL mRNA expression significantly, whereas no difference in PRL transcription levels were observed following treatment with BPA. It is interesting to note that the patterns of pituitary GH and PRL expression were similar to those observed for dose-dependent ED responses. Vehicle alone did not induce GH or PRL expression.
Effects of co-administration of EDs and an ER antagonist on GH mRNA expression
In order to gain new insights into ED activities in body growth and development, we examined whether or not ERs play a role in ED-induced GH expression. Rats were treated with or without the ER antagonist ICI 182780 at 30 min prior to stimulation with high doses (600 mg/kg BW) of OP, NP or BPA, and then real-time quantitative PCR was used to determine the GH mRNA expression levels 48 h after the last injection ( Fig. 2A) . Although GH mRNA expression was induced significantly in response to OP or NP alone (600 mg/kg BW), co-treatment with ICI 182780 attenuated these levels significantly. GH mRNA expression levels were also elevated following treatment with EE (positive control), but this upregulation was inhibited completely by co-treatment with ICI 182780. As expected, PRL mRNA expression was also influenced by co-treatment with the agonist. High PRL mRNA expression levels were observed following administration of EE, OP or NP alone, whereas these effects were diminished significantly by cotreatment with ICI 182,780 (Fig. 2B) . No significant effect on PRL mRNA expression was observed following treatment with BPA, with or without the agonist. Taken together, these results suggest 
Effects of co-administration of EDs and an ER antagonist on GH protein expression
Western blot analysis and IHC were used to examine the involvement of ERs in pituitary GH responses to xenoestrogens at the translational level (Fig. 3) . We observed a significant induction in GH protein expression 48 h after the final injection with EE, OP, NP or BPA (600 mg/kg BW). However, these increased levels of expression were attenuated significantly by co-treatment with the ER antagonist ICI 182780. Vehicle alone did not induce GH expression. Similarly, a high level of PRL protein expression was observed 48 h after induction with EE or the xenoestrogens, while co-treatment with the ER antagonist blocked this upregulation completely (Fig. 4) . Vehicle alone did not induce PRL expression.
Similar results were observed in the anterior lobe of the pituitary. IHC analysis demonstrated GH protein expression following ED treatment, whereas no signals were detected after co-exposure to ICI 182780 (Fig. 5) . Thus, EE administration resulted in a significant induction of GH protein expression in the rat pituitary gland, whereas pretreatment with ICI 182780 completely abolished this upregulation (Figs. 3 and 5) . We also observed a correlation between the changes in GH and PRL protein levels in response to estrogenic EDs (OP, NP or BPA). These findings suggest that exposure to these chemicals during critical windows of develop- Fig. 2 . Effect of an anti-estrogen on induction of GH and PRL mRNA transcription by EDs. The roles of ERs in ED-induced transcription of GH and PRL mRNA were examined by cotreating rats (n=6 per group) with ICI 182780 and OP, NP or BPA, as well as with the positive (EE) and negative (corn oil; VE) controls. The rats were exposed to ICI 182780 (10 -7 M) for 30 min prior to ED exposure and euthanized 48 h after treatment. Following RNA extraction from the pituitary glands, the GH (A) and PRL (B) mRNA expression levels were measured by realtime quantitative PCR. The mRNA levels were normalized by amplification of HPRT. The data were analyzed by one-way ANOVA followed by Tukey's multiple comparison test and are presented as means ± SD. a, P<0.05 vs. vehicle; b, P<0.001 vs. vehicle; c, P<0.05 vs. estrogenic compound alone.
Fig. 3. Effect of an anti-estrogen on induction of GH protein expression.
The involvement of ERs in ED-induced GH translation was examined by co-treating rats (n=6 per group) with ICI 182780 and OP, NP or BPA, as well as with the positive (EE) and negative (corn oil; VE) controls. The rats were exposed to pure ICI 182780 (10 -7 M) for 30 min prior to ED exposure and euthanized at 48 h after treatment. Following protein extraction from the pituitary glands, the GH protein levels were measured by immunoblot analysis. The data were analyzed by one-way ANOVA followed by Tukey's multiple comparison test and are presented as means ± SD. a, P<0.05 vs. vehicle; b, P<0.001 vs. vehicle; c, P<0.05 vs. estrogenic compound alone. ment may induce dysregulation of GH expression and that ERs are involved in ED-induced molecular events in the pituitary.
Discussion
Even at very low levels, EDs can cause biological and toxicological effects by binding hormone receptors, mimicking hormones or blocking their activities [29, 30] . In addition, some EDs may stimulate or inhibit enzymes that play essential roles in hormone synthesis [24, 26] . These environmental EDs may function during different critical windows of development, exerting their adverse effects through a variety of molecular interactions. The potential consequences of these activities include abnormal hormonal regulation and gene expression, which may adversely affect reproductive, immunological and neurological function(s) [31] . The best known class of EDs are the xenoestrogens, which can have potentially detrimental impacts on humans and/or wildlife however, the degree of influence of these EDs depends upon their estrogenicity [25] . For example, although diethylstilbestrol (DES) exhibits considerable estrogenicity and potency [32, 33] , other phenol products such as OP, NP and BPA exert only weak estrogenicity [34, 35] . In our previous studies, we demonstrated that a single ED treatment with OP, NP and BPA could induce increased uterine weight and initiate transcription of ER-regulated genes in vivo [24] . Furthermore, exposure to these environmental chemicals resulted in increased expression of CaBP-9k mRNA and protein [25] . CaBP-9k is a useful biomarker for detecting estro- genic ED activity, and its induction in immature rats suggests that estrogenic ED activity may involve ERs and ER-mediated pathways in vitro and in vivo. Recently, xenoestrogens have been reported to play a role in body growth and development, and BPA has been shown to influence the induction of PRL secretion [36, 37] . E2 and certain xenoestrogens have been shown to modulate PRL expression, and exposure to EDs has been shown to increase PRL transcription significantly in a rat pituitary cell line [9] . These findings suggested that PRL is an estrogen responsive gene that could serve as an biomarker for assessing the estrogenicity of EDs. However, only limited information is available regarding the effects of estrogenic EDs on other members of this growth-promoting hormone family, such as GH. In addition, there is no consensus with respect to whether or not E2 or estrogenic EDs can impact GH expression.
GH is an important hormone in growth, development and body composition and plays a key role in promotion of postnatal longitudinal growth [1] . Furthermore, it is known to be an intracellular modulator for metabolism of lipids and carbohydrates and for nitrogen and minerals [38] . Recently, GH has been shown to exert a direct effect on the brain, modulating emotion, the stress response and behavior [39] . In the present study, immature female rats were employed as an in vivo model for examining the biological effects of EDs on GH expression. PRL expression was used as a marker for estrogenic activity. The rat pituitary gland was examined 48 h after treatment with these chemicals, and high doses (600 mg/kg BW) of OP and NP were found to induce a significant increase in GH transcription, whereas no difference in the GH mRNA level was detected following treatment with BPA. As expected, a single dose of the positive control, EE (50 μg/kg BW), increased GH mRNA expression significantly. We observed a correlation between the patterns of pituitary GH and PRL expression, which showed similar dose-dependent ED responses. At 48 h after the final injection, we observed significant induction of GH protein expression by high doses of OP, NP and BPA. In addition, examination of the anterior lobe of the pituitary by IHC confirmed GH induction at the translational level. GH and PRL are released primarily by the anterior pituitary in all vertebrates [40] , and a strong correlation between GH and PRL expression has been shown at both the mRNA and protein levels [41] . Furthermore, exposure to xenoestrogens induces both GH and PRL expression at 24 h in GH3 rat pituitary cells (unpublished data), suggesting that these molecular events involve an ER-mediated response. It is of interest that BPA did not induce GH or PRL mRNA expression at any dose, although the translational (protein) levels of GH and PRL were induced by BPA in both the immunoblot and IHC results, suggesting that these GH and PRL protein levels appear to be controlled by BPA in a post-transcriptional manner in these cells. In addition, the different responses of GH or PRL at the mRNA and protein levels may be explained by the translational efficiency evoked by this ED.
Estrogen plays an important role in many physiological processes and in development of reproductive organs, bone, liver and cardiovascular systems [19] . Previous studies have indicated that E2 is a critical factor in the regulation of many pituitary hormones [42] and that it can influence both hormone synthesis and secretion [12] . As such, E2 performs a pivotal role in human growth, since it stimulates growth by increasing secretion of pituitary GH and exerting a direct effect on the growth plates [5] . In mammals, the anterior pituitary produces both PRL and GH [10] , and synthesis and release of these hormones occur in response to neural and endocrine signals [11] . Classically, E2 influences regulation of pituitary hormones such as GH and PRL, by binding to its nuclear receptor (ER) [42] . Interactions between these ERs and estrogen responsive elements (ERE) in the promoters of many genes then leads to the regulation of gene expression [43] . Functionally, ERs mediate pituitary cell responsiveness to estrogens [28] and thus, estrogen may influence GH3 cell growth and increase PRL release [9] . In addition, co-treatment with ICI 182780 antagonizes E2-induced PRL secretion [44] , suggesting that ERs play a physiological role in mediating PRL release. In the present study, only a high dose of OP, NP or BPA resulted in significant induction of GH transcription and/or translation in the female rat pituitary gland, indicating that the binding affinity of these chemicals to ER appear to be far less that that of endogenous estrogen, resulting in a very weak estrogenic effect. In addition, it can be concluded that the effects of OP, NP and BPA appear to be primary actions at the rat pituitary gland through ER, but we cannot rule out the possibility of secondary changes through the rat hypothalamus.
Two types of ERs have been identified, ERα and ERβ, and these ERs share a common structural architecture [45, 46] as well as certain functional characteristics [47] . However, the molecular mechanisms underlying their control of genes remain distinct, and their distribution differs between estrogenic target tissues [48] . ERα is expressed primarily in the pituitary gland, whereas ERβ is found preferentially in the preoptic area of the hypothalamus [13, 14, 49] . In the present study, we demonstrated transcriptional and translational induction of pituitary GH in immature female rats following exposure to OP, NP or BPA. The ER antagonist ICI 182780 was used to confirm the involvement of ERs in these ED responses and to provide insights into the mechanism underlying ED activity in this estrogen target tissue. Pretreatment with the ER antagonist abolished ED-induced GH expression in the rat pituitary at both the transcriptional and translational levels. Furthermore, IHC analysis of the anterior lobe indicated the presence of GH protein expression in positively-stained cells following ED treatment, whereas no signals were detected following co-exposure with ICI 182780, as seen in Fig. 5 . These results confirm that ERs play a crucial role in mediating ED-induced molecular events. As expected, treatment with EE and xenoestrogens, except for BPA, also induced significant increases in PRL mRNA and protein levels, and this effect was inhibited significantly by an ER antagonist. These results suggest that the biological responses to OP, NP or BPA exposure may involve ERs and ER-mediated responses in the pituitary gland.
The anterior pituitary comprises five distinct cell types, of which the lactotrophs and somatotrophs may derive from a common stem cell that expresses both GH and PRL during certain stages of development [14] . Somatotrophs are also called acidophil GH-releasing cells and are abundant in the pituitary [1] . In this estrogen target tissue, GH synthesis and release are modulated by two hypothalamic peptides, GH-releasing hormone and somatostatin [50] . E2 and ERα regulate PRL synthesis and secretion from the lactotrophs in the anterior pituitary [51] , and ERα is required for positive regulation of PRL expression in the pituitary [14] . In addition, this ER may be a physiological mediator for xenoestrogen induction of GH and/or PRL gene expression and secretion in vitro (unpublished data). Thus, it is likely that this transcription factor plays a critical role in ED-induced responses. In the present study, we used immature rats to confirm our earlier in vitro results in GH3 rat pituitary cells.
In conclusion, we have demonstrated for the first time that in vivo exposure to OP, NP or BPA results in increased induction of pituitary GH mRNA and that OP and NP induce GH protein expression in the rat pituitary gland. Furthermore, we demonstrated that these EDs may act via an ER-mediated signaling pathway. These results provide important evidence suggesting that ED-induced dysregulation of pituitary GH expression can occur during critical windows of development. Thus, this information may help to elucidate the potential impact of EDs on body growth and development in vivo and to predict the health risk of ED exposure to humans and wildlife.
